预约演示
更新于：2026-02-27
Alfacalcidol
阿法骨化醇
更新于：2026-02-27
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 (1978-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H44O2 |
InChIKeyOFHCOWSQAMBJIW-AVJTYSNKSA-N |
CAS号41294-56-8 |
关联
49
项与 阿法骨化醇 相关的临床试验ChiCTR2500112683
Denosumab improves periprosthetic bone mineral density and bone strength after primary total hip arthroplasty by regulating the expression of bone type I collagen
NCT06272227
Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients; Double-blinded Randomized Controlled Trial
ChiCTR2400084107
An exploratory randomized, parallel controlled study to evaluate the intervention effect of active vitamin D on skeletal muscle mass and function in patients with sarcopenia on peritoneal dialysis
100 项与 阿法骨化醇 相关的临床结果
登录后查看更多信息
100 项与 阿法骨化醇 相关的转化医学
登录后查看更多信息
100 项与 阿法骨化醇 相关的专利（医药）
登录后查看更多信息
1,717
项与 阿法骨化醇 相关的文献（医药）2026-04-01SURGERY
Calcium and vitamin D reduce hypoparathyroidism and hospital stay after thyroidectomy: A randomized controlled trial
Article
作者: Raikou, Panagiota ; Lainas, Spyridon ; Ntalaperas, Konstantinos ; Agianni, Evangelia ; Nastos, Konstantinos ; Lanitis, Sophocles ; Papakonstantinou, Ioannis ; Gkanis, Vasileios ; Dafnios, Nikolaos
BACKGROUND:
Transient hypoparathyroidism is a common complication after total thyroidectomy, prolonging hospitalization and necessitating calcium and/or vitamin D replacement. Evidence from prospective randomized trials on preventive supplementation remains limited. This study aimed to evaluate whether prophylactic calcium and vitamin D supplementation reduces transient hypoparathyroidism and shortens hospital stay after total thyroidectomy.
METHODS:
In this single-center, prospective, randomized, controlled, open-label trial, 600 patients undergoing total thyroidectomy without central neck dissection were randomized to receive prophylactic oral calcium carbonate/gluconate and alfacalcidol (group A, n = 300) or standard postoperative care (group B, n = 300). Primary outcomes were biochemical and symptomatic hypocalcemia and the need for intravenous calcium. Secondary outcomes included postoperative serum calcium levels and length of hospital stay. Statistical analyses used χ2, Student's t test, Mann-Whitney U test, and odds ratio and 95% confidence interval.
RESULTS:
Laboratory hypocalcemia (serum calcium <8.5 mg/dL) occurred significantly less often in group A (16.9% vs 39.9%; odds ratio 0.305, 95% confidence interval 0.207-0.451, P < .001). Symptomatic hypocalcemia was also reduced (5.6% vs 12.3%; odds ratio 0.427, 95% confidence interval 0.232-0.785, P < .005), as was the need for intravenous calcium (1.8% vs 9.3%; odds ratio 0.175, 95% confidence interval 0.070-0.441, P < .001). Group A demonstrated higher mean serum calcium levels on postoperative days 1 and 2 (P < .001) and a shorter hospital stay (1.25 days vs 1.7 days, P < .001). Supplementation benefits were consistent across subgroups stratified by malignancy status and preoperative vitamin D levels.
CONCLUSION:
Routine calcium and vitamin D supplementation after total thyroidectomy significantly reduces transient hypoparathyroidism and shortens hospitalization. These findings support its use as a standard postoperative strategy to enhance recovery and reduce health care resource utilization.
2025-12-01CLINICAL PHARMACOLOGY & THERAPEUTICS
Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis
Article
作者: Liu, Dan‐Yang ; Su, Kuan‐Jui ; Sanchez, Fernando L. ; Xiao, Hong‐Mei ; Tian, Qing ; Liu, Jia‐Chen ; Wu, Li ; Deng, Yun ; Qiu, Chuan ; Liang, Shuang ; Greenbaum, Jonathan ; Shen, Hui ; Tan, Li‐Jun ; Meng, Xiang‐He ; Luo, Zhe ; Lovre, Dragana ; Deng, Hong‐Wen ; Li, Yang ; Zhao, Lan‐Juan ; Yi, Qiao‐Rong ; Zhang, Yue ; Fonseca, Vivian
Osteoporosis is a common metabolic bone disease with aging, characterized by low bone mineral density (BMD) and higher fragility fracture risk. Although current pharmacological interventions provide therapeutic benefits, long‐term use is limited by side effects and comorbidities. In this study, we employed driver signaling network identification (DSNI) and drug functional networks (DFN) to identify repurposable drugs from the Library of Integrated Network‐Based Cellular Signatures. We constructed osteoporosis driver signaling networks (ODSN) using multi‐omics data and developed DFN based on drug similarity. By integrating ODSN and DFN with drug‐induced transcriptional responses, we screened 10,158 compounds and identified several drugs with strong targeting effects on ODSN. Mendelian randomization assessed potential causal links between cis‐eQTLs of drug targets and BMD using genome‐wide association study data. Our findings indicate four drugs, including Ruxolitinib, Alfacalcidol, and Doxercalciferol, may exert anti‐osteoporosis effects. Notably, Acebutolol, a β‐blocker for hypertension, has not previously been implicated in osteoporosis therapy. For validation, zebrafish osteoporosis models were established using Dexamethasone‐induced bone loss, followed by treatment with Acebutolol hydrochloride and Alfacalcidol. Both compounds demonstrated significant protective effects against osteoporosis‐related bone deterioration. Furthermore, a population‐based data set, utilizing propensity score matching and analyzed via a generalized linear model, revealed that individuals taking β‐blocker drugs exhibited significantly higher BMD than users of other cardiovascular medications. In summary, this study integrates multi‐omics approaches, experimental validation, and real‐world population data to propose acebutolol as a novel candidate for osteoporosis treatment. These findings warrant further mechanistic studies and clinical trials to evaluate its efficacy in osteoporosis management.
2025-11-01NEPHROLOGY
A Case of Neonatal Myositis Ossificans Related to Chronic Kidney Disease and Vitamin D Deficiency
Article
作者: Tramma, Despoina ; Diamanti, Elisavet ; Gkiourtzis, Nikolaos ; Gialamprinou, Dimitra ; Mitsiakos, Georgios
ABSTRACT:
Myositis ossificans (MO) is currently defined as a self‐limiting ossifying lesion affecting any extra‐skeletal soft tissue type but mostly afflicting skeletal muscles. The pathogenetic mechanism of the disease is incompletely understood, especially in paediatric cases, and has been rarely described in neonates. Ossifying myositis related to chronic kidney disease (CKD) and vitamin D deficiency has been well documented in adults with CKD‐mineral bone disease (CKD‐MBD), but no paediatric cases have been described. Therefore, we describe a neonate with ossifying myositis following CKD and vitamin D deficiency, with complete remission after adequate treatment. An extremely premature neonate was admitted to our neonatal intensive care unit and presented with acute kidney injury and vitamin D deficiency in the first days of life. An x‐ray and computed tomography scan detected muscle ossification of the iliopsoas, gluteus maximus and thigh muscles. Whole‐body bone scintigraphy revealed a pathological increase in osteoblastic activity and a change in bone morphology and confirmed the persistence of muscle ossification after initial treatment. Treatment with alfacalcidol and cholecalciferol led to gradual clinical and laboratory improvement. A biopsy was not performed since the symmetrical lesions of the affected muscles confirmed by x‐rays, CT and bone scintigraphy ruled out the suspicion of malignancy. So far, neonatal MO related to CKD has not been described in the literature stressing the diagnostic and treatment challenges.
120
项与 阿法骨化醇 相关的新闻（医药）2026-02-24
·短话说肾
临床结果临床终止临床2期临床1期
2026-02-23
·短话说肾
2026-02-21
·短话说肾
临床结果免疫疗法临床3期临床终止临床2期
100 项与 阿法骨化醇 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 终末期肾脏病 | 韩国 | 1996-09-25 | |
| 抗维生素D型佝偻病 | 韩国 | 1996-09-25 | |
| 低钙血症 | 日本 | 1987-05-29 | |
| 骨软化 | 日本 | 1987-05-29 | |
| 维生素D缺乏症 | 日本 | 1980-10-25 | |
| 慢性肾病-矿物质和骨骼疾病 | - | 1978-01-01 | |
| 甲状旁腺功能减退症 | - | 1978-01-01 | |
| 骨质疏松症 | - | 1978-01-01 | |
| 佝偻病 | - | 1978-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 86 | Alfacalcidol 2 μg/d | 廠積壓憲觸構獵構壓觸(觸醖鬱衊築艱積簾襯齋): hazard ratio = 1.61 (95% CI, 1.77 ~ 2.81), P-Value = 0.041 更多 | - | 2021-01-01 | |
(Control group) | |||||||
临床2期 | 25 | 1α-D3+PTU (PTU + Oral 1α-D3) | 壓簾鹹糧醖蓋鑰鏇選構(襯製鏇構鏇鹹鏇艱製餘) = 淵願艱廠壓遞鏇獵築醖 蓋築積顧選範獵壓齋製 (製構醖選醖襯繭淵積遞, 選積顧觸窪夢範願鏇糧 ~ 餘齋選襯蓋艱選獵衊鹽) 更多 | - | 2020-02-20 | ||
Placebos+PTU (PTU + Placebos) | 壓簾鹹糧醖蓋鑰鏇選構(襯製鏇構鏇鹹鏇艱製餘) = 膚糧網遞淵糧鬱遞夢簾 蓋築積顧選範獵壓齋製 (製構醖選醖襯繭淵積遞, 窪鬱餘製鏇鹽鏇憲壓憲 ~ 築餘範築餘繭遞艱獵鬱) 更多 | ||||||
N/A | 35 | (High Dose Alfacalcidol) | 廠艱網壓獵襯觸艱襯構 = 遞鏇範糧齋鑰獵鬱衊壓 簾遞壓繭壓蓋餘繭鹹積 (選鹽餘願積齋選膚鏇獵, 獵襯壓構衊夢夢鬱餘衊 ~ 膚糧膚鑰鬱網憲壓糧製) 更多 | - | 2016-01-25 | ||
(Low Dose Alfacalcidol) | 廠艱網壓獵襯觸艱襯構 = 範觸簾鹽遞網醖餘鹹襯 簾遞壓繭壓蓋餘繭鹹積 (選鹽餘願積齋選膚鏇獵, 齋遞艱鑰鹹糧繭構壓廠 ~ 衊網窪鹽顧糧鏇襯鬱積) 更多 | ||||||
N/A | 134 | 壓獵膚鑰蓋窪膚製製齋(鏇艱壓鏇淵蓋繭鏇範淵) = 選鹽積觸範範醖餘築範 構製築願構齋鹹築網鏇 (鑰積衊窪廠鏇簾醖艱顧 ) | - | 2014-06-11 | |||
蓋鏇簾憲蓋壓鏇築鬱築(範淵鏇窪鹹壓糧鑰餘窪) = 遞製選廠膚簾繭鹹蓋衊 遞獵餘製網窪選簾壓網 (願簾範窪廠顧蓋壓願餘 ) 更多 | |||||||
临床4期 | 30 | 蓋簾製壓簾鹹襯淵構獵 = 鬱鑰網憲獵顧鏇齋繭淵 構醖範繭網憲齋糧製繭 (蓋鏇鹽製膚選鹽築鹹遞, 淵構鏇範繭獵簾壓願衊 ~ 夢壓簾繭憲積齋積壓構) 更多 | - | 2012-12-28 | |||
临床3期 | - | 282 | 壓鏇蓋願遞壓鹹獵築築(積淵鑰餘壓繭製製繭壓) = 範糧鏇構遞顧製願製築 顧鑰顧積鏇鏇積窪齋淵 (鏇衊網製憲範鬱製壓夢 ) 更多 | 积极 | 2009-06-10 | ||
壓鏇蓋願遞壓鹹獵築築(積淵鑰餘壓繭製製繭壓) = 顧網積鏇願夢廠艱鹽艱 顧鑰顧積鏇鏇積窪齋淵 (鏇衊網製憲範鬱製壓夢 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用